<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1911">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136287</url>
  </required_header>
  <id_info>
    <org_study_id>SEVERAL</org_study_id>
    <nct_id>NCT05136287</nct_id>
  </id_info>
  <brief_title>The Objective is to Evaluate and Compare the Weight Loss in Patients With DM2 Treated With the Different aGLP1 for the First Time. Secondary Endpoints Are HbA1c Reduction, Changes in Quality of Life and Physical Activity and the Safety of These Drugs.</brief_title>
  <acronym>SEVERAL</acronym>
  <official_title>SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jose Seijas Amigo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinico Universitario de Santiago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction:&#xD;
&#xD;
      GLP-1 receptor agonists (aGLP1) act increasing pancreatic insulin secretion in response to&#xD;
      the glucose, they reduce glucagon secretion and reduce appetite by acting in the central&#xD;
      level. Several aGLP1 were approved through different clinical trials where they showed&#xD;
      efficacy in the glycemic control and reduction in cardiovascular events. They also showed&#xD;
      weight loss in different clinical trials with patients with diabetes mellitus 2 (DM2) and&#xD;
      also in specific clinical trial where the weight loss was the primary endpoint (STEP study).&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The objective is to evaluate and compare the weight loss in patients with DM2 treated with&#xD;
      the different aGLP1 for the first time. Secondary endpoints are HbA1c reduction, changes in&#xD;
      quality of life and physical activity and the safety of these drugs.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      It is a postauthorization, multicenter, non-randomized and prospective study. Patients that&#xD;
      will start treatment for the first time with aGLP1 will be recruited in 10 primary care&#xD;
      centers in SERGAS Galician Hospitals for a period of 6 months and 44 weeks of follow-up. The&#xD;
      primary endpoint will be to evaluate the wight loss with the different aGLP1 and the&#xD;
      secondary endpoint will be HbA1c reduction, changes in the quality of life through the&#xD;
      EuroQol-5D and changes physical activity through the SF-12 questionnaire, and also the safety&#xD;
      of these drugs. The sample size will be of 360 patients.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      Previous studies showed efficacy in weight loss with semaglutide about (3,6-4,9 kg), while&#xD;
      with other aGLP1 the weight loss was smaller , about (0,86-2,96 kg).&#xD;
&#xD;
      Based in these data and with a 5% of significance level, a weight loss average in the aGLP1&#xD;
      group of 2,5 kg, average in semaglutide group of 4,2 kg, and combination deviation of 3,0kg,&#xD;
      including 360 subjects we will have a statistical power above 90% to detect differences&#xD;
      through T-test for independent samples.&#xD;
&#xD;
      The justification of this simple size was performed with the statistical software SPSS 3.0&#xD;
&#xD;
      Conclusions:&#xD;
&#xD;
      The SEVERAL study will try to provide information about weight loss efficacy, changes in&#xD;
      quality of life, physical activity and safety of the aGLP1in patients with DM2 that start&#xD;
      treatment with these drugs in the real life (Real-World Evidence)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>11 months</time_frame>
    <description>The primary outcome will be by assesment of % weight loss</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>11 months</time_frame>
    <description>Assesment the weiht loss by reduction in Kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>11 months</time_frame>
    <description>Assesment of changes in BMI ( weight (Kg) and height (cm) will be combined to report BMI in kg/m^2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c values</measure>
    <time_frame>11 months</time_frame>
    <description>HbA1c changes will be assessed during the study by routine sample tests (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life</measure>
    <time_frame>11 months</time_frame>
    <description>By using the questionnaire called EuroQol EQ-5D-3L assessment. It has 2 parts, the first one has 5 questions with 3 possible answers (5 dimensions and 3 levels), so each health status has a rate called EVA from 1,0000 (the highest value) to - 0,5095 (the worst health status).&#xD;
The second part is a visual self-assessment between 0 (the worst health status) and 100 (the best health status). https://euroqol.org/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical Activity</measure>
    <time_frame>11 months</time_frame>
    <description>By using the questionnaire called EuroQol SF-12 assessment.For each of the 8 dimensions, the items are coded, added and transformed on a scale that ranges from 0 (the worst health status for that dimension) to 100 (the best health status).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing adverse events</measure>
    <time_frame>11 months</time_frame>
    <description>Gastrointestinal events; hypoglycemia; pancreatitis; fatigue; ijection reactions; Diabetic retinopathy; cardiac events and other possible events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Weight Loss</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Quality of Life</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Diabetes mellitus 2 patients with obesity</arm_group_label>
    <description>Patients that meet criteria to start treatment with GLP-1 receptor agonists (dulaglutide; exenatide; liraglutide; lixisenatide )</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 receptor agonist</intervention_name>
    <description>Patients are included after GLP1 agonists prescription , at the first dispensation</description>
    <arm_group_label>Diabetes mellitus 2 patients with obesity</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Diabetes mellitus 2 with another oral antidibetic and obesity (BMI&#xD;
        &gt; 30Kg/m2) that present uncontrolled HbA1c. With a first prescription of GLP-1 receptor&#xD;
        agonists.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years old or over&#xD;
&#xD;
          -  To start with the first funded dose of GLP1 receptor agonists ( BMI &gt; 30Kg/m2)&#xD;
&#xD;
          -  Treated with another oral antidiabetic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetic retinopahty and family history of thyroid cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Seijas Amigo</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico Santiago de Compostela</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Seijas Amigo, Pharmacist</last_name>
    <phone>+34981955764</phone>
    <email>jose.seijas.amigo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Begoña Cardeso Paredes, Biologist</last_name>
    <phone>+34981955247</phone>
    <email>begocardeso@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Salud de Culleredo</name>
      <address>
        <city>Culleredo</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de Fene</name>
      <address>
        <city>Fene</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana Belen Ponce Piñon</last_name>
    </contact>
    <investigator>
      <last_name>Ana Belen Ponce Piñon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de Ribeira</name>
      <address>
        <city>Ribeira</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosa Ana Castelo Dominguez</last_name>
    </contact>
    <investigator>
      <last_name>Rosa Ana Castelo Dominguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Seijas Amigo, Pharmacist</last_name>
      <phone>+34981955764</phone>
      <email>jose.seijas.amigo@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Begoña Cardeso Paredes, Biologist</last_name>
      <phone>+34981955247</phone>
      <email>begocardeso@gmial.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Seijas Amigo, Pharmacist</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moises Rodriguez Mañero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego Rodriguez Penas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Begoña Cardeso Paredes</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angel Salgado Barreiro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Ramon Gonzales Juanatey</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de Ribadeo</name>
      <address>
        <city>Ribadeo</city>
        <state>Lugo</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria del Mar Gago Garcia</last_name>
    </contact>
    <investigator>
      <last_name>Maria del Mar Gago Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de Vilalba</name>
      <address>
        <city>Vilalba</city>
        <state>Lugo</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Agustina Fernandez Perez</last_name>
    </contact>
    <investigator>
      <last_name>Maria Agustina Fernandez Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de O Carballiño</name>
      <address>
        <city>O Carballiño</city>
        <state>Ourense</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Montserrat Fernandez Montenegro</last_name>
    </contact>
    <investigator>
      <last_name>Montserrat Fernandez Montenegro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Valmiñor</name>
      <address>
        <city>Nigrán</city>
        <state>Pontevedra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de O Ventorrillo</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud de San Roque</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Virxe Peregrina</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Marta Rodriguez Barreiro</last_name>
    </contact>
    <investigator>
      <last_name>Marta Rodriguez Barreiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://cima.aemps.es/cima/dochtml/ft/114956002/FT_114956002.html</url>
    <description>Dulaglutide datasheet</description>
  </link>
  <link>
    <url>http://cima.aemps.es/cima/dochtml/ft/114956002/FT_114956002.html</url>
    <description>Tofacitinib datasheet</description>
  </link>
  <link>
    <url>http://cima.aemps.es/cima/dochtml/ft/111696003/FT_111696003.html</url>
    <description>Exenatide datasheet</description>
  </link>
  <link>
    <url>http://cima.aemps.es/cima/dochtml/ft/09529002/FT_09529002.html</url>
    <description>Liraglutide datasheet</description>
  </link>
  <link>
    <url>http://cima.aemps.es/cima/dochtml/ft/12811005/FT_12811005.html</url>
    <description>Lixisenatide datasheet</description>
  </link>
  <link>
    <url>http://cima.aemps.es/cima/dochtml/ft/117251002/FT_117251002.html</url>
    <description>Semaglutide datasheet</description>
  </link>
  <reference>
    <citation>DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013 Aug;36 Suppl 2:S127-38. doi: 10.2337/dcS13-2011.</citation>
    <PMID>23882037</PMID>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602.</citation>
    <PMID>9742976</PMID>
  </reference>
  <reference>
    <citation>Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9. Erratum in: Lancet. 2010 Sep 18;376(9745):958. Hillage, H L [corrected to Hillege, H L].</citation>
    <PMID>20609967</PMID>
  </reference>
  <reference>
    <citation>Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21. Review.</citation>
    <PMID>19545590</PMID>
  </reference>
  <reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </reference>
  <reference>
    <citation>Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.</citation>
    <PMID>27295427</PMID>
  </reference>
  <reference>
    <citation>Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.</citation>
    <PMID>31189511</PMID>
  </reference>
  <reference>
    <citation>Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018 Apr;6(4):275-286. doi: 10.1016/S2213-8587(18)30024-X. Epub 2018 Feb 1.</citation>
    <PMID>29397376</PMID>
  </reference>
  <reference>
    <citation>Marso SP, Holst AG, Vilsbøll T. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2017 Mar 2;376(9):891-2. doi: 10.1056/NEJMc1615712.</citation>
    <PMID>28249135</PMID>
  </reference>
  <reference>
    <citation>Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.</citation>
    <PMID>33567185</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinico Universitario de Santiago</investigator_affiliation>
    <investigator_full_name>Jose Seijas Amigo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>semaglutide</keyword>
  <keyword>GLP1 receptor agonists</keyword>
  <keyword>diabetes mellitus 2</keyword>
  <keyword>weight loss</keyword>
  <keyword>BMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

